Literature DB >> 24691877

Seasonal influenza vaccination and technologies.

Anne N Nafziger1, David S Pratt.   

Abstract

Seasonal influenza is a serious respiratory illness that causes annual worldwide epidemics resulting in significant morbidity and mortality. Influenza pandemics occur about every 40 yrs, and may carry a greater burden of illness and death than seasonal influenza. Both seasonal influenza and pandemic influenza have profound economic consequences. The combination of current vaccine efficacy and viral antigenic drifts and shifts necessitates annual vaccination. New manufacturing technologies in influenza vaccine development employ cell culture and recombinant techniques. Both allow more rapid vaccine creation and production. In the past 5 years, brisk, highly creative activity in influenza vaccine research and development has begun. New vaccine technologies and vaccination strategies are addressing the need for viable alternatives to egg production methods and improved efficacy. At present, stubborn problems of sub-optimal efficacy and the need for annual immunization persist. There is an obvious need for more efficacious vaccines and improved vaccination strategies to make immunization easier for providers and patients. Mitigating this serious annual health threat remains an important public health priority.
© 2014, The American College of Clinical Pharmacology.

Entities:  

Keywords:  Human/immunology/*prevention & control; Influenza; Influenza A; Influenza B; Influenza vaccines

Mesh:

Substances:

Year:  2014        PMID: 24691877     DOI: 10.1002/jcph.299

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  4 in total

1.  Intranasal Immunization Using Mannatide as a Novel Adjuvant for an Inactivated Influenza Vaccine and Its Adjuvant Effect Compared with MF59.

Authors:  Shu-Ting Ren; Xue-Mei Zhang; Peng-Fei Sun; Li-Juan Sun; Xue Guo; Tian Tian; Jian Zhang; Qi-Yuan Guo; Xue Li; Li-Jun Guo; Jin Che; Bing Wang; Hui Zhang
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

2.  Identification and in vivo Efficacy Assessment of Approved Orally Bioavailable Human Host Protein-Targeting Drugs With Broad Anti-influenza A Activity.

Authors:  Theresa Enkirch; Svenja Sauber; Danielle E Anderson; Esther S Gan; Dimitar Kenanov; Sebastian Maurer-Stroh; Veronika von Messling
Journal:  Front Immunol       Date:  2019-06-05       Impact factor: 7.561

3.  Barriers Associated with the Uptake Ratio of Seasonal Flu Vaccine and Ways to Improve Influenza Vaccination Coverage among Young Health Care Workers in Poland.

Authors:  Sylwia Kałucka; Izabela Grzegorczyk-Karolak
Journal:  Vaccines (Basel)       Date:  2021-05-20

4.  Knowledge, awareness and practices towards seasonal influenza and its vaccine: implications for future vaccination campaigns in Jordan.

Authors:  Eman Y Abu-Rish; Eman R Elayeh; Lubabah A Mousa; Yasser K Butanji; Abla M Albsoul-Younes
Journal:  Fam Pract       Date:  2016-08-27       Impact factor: 2.267

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.